<i>Aedes aegypti</i> database from SAGO traps. by Jesús A. Aguilar-Durán (9931967)

“…IVM treatment reduced the number of females per trap per week from 3.29 ± 0.24 to 2.41 ± 0.20 (33.7% reduction), AGO from 1.58 ± 0.17 to 0.25 ± 0.05 (85.2% reduction), and AGO + IVM from 1.49 ± 0.17 to 0.53 ± 0.08 (67.78% reduction), based on Henderson’s formula. We observed a non-significant increase in the control area (no treatment provided) in the mosquito populations, increasing from 2.94 ± 0.24 in the pretreatment period to 3.25 ± 0.28 of the post treatment period.…”

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Comparison of serum VEGF-A165 concentrations pre-bevacizumab administration in patients with increased VEGF-A post-bevacizumab administration and those with decreased VEGF-A. by Masashi Okawa (8951294)

Subjects:

Microscopic view of <i>spirulina</i> spp. by Maha Rehman (17114332)

Subjects:

Supplementary data file of graphs. by Maha Rehman (17114332)

Subjects:

Fig 3 - by Maha Rehman (17114332)

Subjects:

Fig 5 - by Maha Rehman (17114332)

Subjects:

Fig 4 - by Maha Rehman (17114332)

Subjects:

The primer sequences of real-time PCR. by Lihan Xu (18778257)

Subjects:

The impact of UV360 on the development of spinal motor neuron axons in zebrafish larvae. by Lihan Xu (18778257)

Subjects:

The impact of UV360 on the locomotor activity of zebrafish larvae. by Lihan Xu (18778257)

Subjects:

The outcomes of transcriptome analyses. by Lihan Xu (18778257)

Subjects:

The impact of UV360 on the viability and developmental progression of zebrafish embryos. by Lihan Xu (18778257)

Subjects:

The impact of UV360 on the neurophysiological activity of zebrafish larvae. by Lihan Xu (18778257)

Subjects:

Clinical characteristics of the study population. by Hun Gi Lee (21526538)

Subjects:

GLM models for predictors of monthly HIV costs. by Drew B. Cameron (10687420)

“…<div><p>Background</p><p>Despite improvements to the cascade of HIV care in East Africa, access to care for non-communicable disease co-morbidities like hypertension (HTN) remains a persistent problem. The integration of care for these conditions presents an opportunity to achieve efficiencies in delivery as well as decrease overall costs for patients. …”

Median cost (USD) per visit breakdown. by Drew B. Cameron (10687420)

“…<div><p>Background</p><p>Despite improvements to the cascade of HIV care in East Africa, access to care for non-communicable disease co-morbidities like hypertension (HTN) remains a persistent problem. The integration of care for these conditions presents an opportunity to achieve efficiencies in delivery as well as decrease overall costs for patients. …”